Okay, but the investment community is not responding with the least bit of enthusiasm and I still think the problem is the statement in the news article: Geron has committed to the U.S. Food and Drug Administration (FDA) that the company will not initiate any new clinical studies under the transferred IND from Mayo Clinic...